Revisiting clinical trial design – more adaptability in Phase I – III?
Elihu H. Estey
What are the genetic and environmental risk factors for chronic lymphoblastic leukemia (CLL)?
What does the TOURMALINE-MM2 study tell us about the use of ixazomib in multiple myeloma?
What are the predictors of ponatinib treatment response?
Michael J. Mauro
Overview of the CLL13 trial: replacing chemotherapy with venetoclax-containing regimens
Julia von Tresckow